Comparative Pharmacology
Head-to-head clinical analysis: CHOLAC versus COLONAID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLAC versus COLONAID.
CHOLAC vs COLONAID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic pH. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
COLONAID acts as a selective 5-HT4 receptor agonist in the gastrointestinal tract, enhancing colonic motility and reducing visceral hypersensitivity. It also exhibits anti-inflammatory properties by inhibiting macrophage activation and cytokine release in colonic mucosa.
15-30 mL (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 mL/day. For hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
COLONAID: 500 mg orally twice daily with meals.
None Documented
None Documented
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Terminal elimination half-life is 18 hours (range 15–22 hours), supporting twice-daily dosing in patients with normal renal function.
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
Renal elimination of unchanged drug accounts for 70% of clearance; biliary/fecal elimination accounts for 25%; 5% is metabolized.
Category C
Category C
Laxative
Laxative